source
- China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slumpBiotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
- Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filingCelldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…